<DOC>
	<DOCNO>NCT00605761</DOCNO>
	<brief_summary>Subject Cystic Fibrosis increase clearance many drug . Based pre-clinical data SB656933 find low clearance high bio-availability . This study characterize PK profile single dose SB656933 patient Cystic Fibrosis . There two group subject . The first group subject receive single dose 50mg SB-656933 . The second group subject receive single dose 300 mg SB-656933 . Subjects first screen eligibility relate cystic fibrosis history . Safety evaluation undertake plasma sample pharmacokinetic analysis collect . Additional blood sample take pharmacodynamic endpoint CD11b GAFS . Subjects require stay overnight 12 hour PK sample collection Day 1 , although may wish . On Day 2 3 , return collection additional safety measurement , plasma blood sample take 24 48 h pharmacokinetics 24h CD11b/GAFS measurement , respectively . A follow visit ( Visit 3 ) make 4-7 day treatment period . Subjects enrol study approximately 3to 7 week ( screen follow-up ) .</brief_summary>
	<brief_title>SD Cystic Fibrosis Study</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Have Cystic Fibrosis Male great equal 18 year age female great equal 16 year age . Must smoker , smoke cigarette use tobacco product regularly last 6 month Must clinically stable change symptom medication , admission hospital , intravenous antibiotic therapy least 2 week study start . Able perform lung function test Lung test reading FEV1 &gt; 40 % predict Lung test FEV1 change &gt; 10 % past 12 month Must normal ECG . Women child bear potential must use effective method contraception . Male subject must agree abstain use condom sexual intercourse use condom/spermicide , addition female partner use another form contraception . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) normal study start . Signed date write informed consent . The parent/guardian must give write informed consent child participate investigation . Adolescents must also sign informed consent The subject able understand follow protocol . Any clinically abnormality find screen part disease cystic fibrosis . problem pancrease fatty feces liver problem sudden weight loss poor nutritional status . high blood pressure infect hepatitis B , hepatitis C , HIV virus History regular alcohol use current nonsmoker use corticosteroid ; regular use high dose NSAIDs , within 2 month study start . positive Burkholderia cepacia , MRSA within last 12 month treatment mycobacterial infection withdrawn oral azithromycin study mark bleed haemoptysis last 12 month . take 4 new chemical entity within last year . donate 500 mL within last 56 day . take part drug trial 30 day take part trial new chemical within last 2 month . drug CYP3A4 , CYP2B6 , CYP2C8 OATP1B1 substrates narrow therapeutic index exclude . use nonprescription drug , include , herbal dietary supplement ( include St John 's Wort ) within 7 day unless permitted Investigator sponsor Consumption grapefruit juice last 7 seven day study start . Pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Lung function</keyword>
	<keyword>Anti-Inflammatory</keyword>
</DOC>